Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials

• Main Authors: Thomas Bieber (Author), Norito Katoh (Author), Eric L. Simpson (Author), Marjolein de Bruin-Weller (Author), Diamant Thaçi (Author), Antonio Torrelo (Author), Angelina Sontag (Author), Susanne Grond (Author), Maher Issa (Author), Xiaoyu Lu (Author), Tracy Cardillo (Author), Katrin Holzwarth (Author), Jacob P. Thyssen (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background Baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, is approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults. Objectives We report integrated baricitinib safety data in patients with up to 3.9-years exposure. Methods Three datasets from the integrated AD c...